Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection.

@article{Karageorgopoulos2014DrugIB,
  title={Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection.},
  author={Drosos E. Karageorgopoulos and Omar El-Sherif and Sanjay Bhagani and Saye Khoo},
  journal={Current opinion in infectious diseases},
  year={2014},
  volume={27 1},
  pages={36-45}
}
PURPOSE OF REVIEW We reviewed the pharmacokinetic interactions between direct-acting antivirals against hepatitis C virus (HCV) and antiretroviral agents. RECENT FINDINGS Most relevant pharmacokinetic studies involve healthy individuals and refer to the already licensed HCV protease inhibitors, boceprevir and telaprevir. Data from a phase II clinical trial question the clinical relevance of the interactions between boceprevir and HIV protease inhibitors. The use of a higher dose of telaprevir… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

Drug interactions with new hepatitis C oral drugs.

Expert opinion on drug metabolism & toxicology • 2015
View 1 Excerpt

Similar Papers

Loading similar papers…